Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT04616131

Evaluating the Prognostic Capability of ctDNA as a Biomarker in Pancreatic Cancer Patients Undergoing Neoadjuvant Chemotherapy

Conditions: Pancreas Cancer

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 500

Sponsor: Northwestern University

Location: Northwestern Medicine Cancer Center Kishwaukee DeKalb Illinois

Summary

For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Eligibility Criteria

Inclusion Criteria: * Biopsy or cytology proven adenocarcinoma of the pancreas * No clinical evidence of metastatic disease on imaging * Age 18 or older * Receiving chemotherapy for non-metastatic pancreatic cancer Exclusion Criteria: * Biopsy proven metastatic disease

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT04616131). StuddyBuddy aggregates publicly available trial information.